Calithera achieves positive topline results in randomized phase 2 ENTRATA study
Calithera Biosciences announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma. The combination doubled the median PFS in heavily pre-treated patients. June 17, 2019